|Previous Section||Index||Home Page|
The MRC has a large portfolio of genetic research, some of which may have relevance to the condition. For example, the MRC funds research on the genetic factors related to learning disorders that has identified a number of candidate genes contributing to learning disability.
Ann Keen: The national service framework for coronary heart disease (March 2000) sets a 10-year framework for action to prevent disease, tackle inequalities, save more lives, and improve the quality of life for people with heart disease. Chapter 4 of the CHD NSF covers stable angina. This chapter sets out how primary care teams and specialists can best help people with angina or suspected angina to relieve their symptoms and reduce their risk of suffering a major cardiovascular event.
When the CHD NSF was written, there was little high-quality evidence to guide practice for refractory angina and it was mentioned only briefly. However, since 1996, a national centre for the management of patients with refractory angina has been developing at the Royal Liverpool and Broadgreen university hospital trust. This is known as the National Refractory Angina Centre (NRAC). In November 2007, the Cheshire and Merseyside cardiac network published the second edition of its guideline on the management and treatment of stable angina. Although not a stable condition, the document contains a detailed section on refractory angina. This guideline is recognised nationally.
The following table provides the number of prescription items prescribed in the community in Sefton primary care trust and England as a whole, that were dispensed in the community in the United Kingdom, for anti-depressant drugs listed in British National Formulary (BNF) section 4.3 for the latest available 12 month period.
|Number of prescription items prescribed in the community in Sefton PCT and England as a whole, that were dispensed in the community in the UK, for anti-depressant drugs listed in BNF section 4.3.|
|November 2007 to October 2008||Number of items ( Thousand )|
Prescribing Analysis and CosT tool (ePACT) system.
Mike Penning: To ask the Secretary of State for Health what estimate he has made of the cost to the NHS of prescriptions of anti-depressant drugs in (a) Hemel Hempstead and (b) Hertfordshire in the last 12 months. 
The British National Formulary classifies anti-depressant drugs within section 4.3. We are able to supply the prescribing costs for drugs within this section for health regions. The latest figures available are for November 2008.
As the areas requested are not health regions we have supplied information for the health regions that best fit those requested (West Hertfordshire primary care trust to represent Hemel Hempstead and West Hertfordshire and East and North Hertfordshire PCTs combined to represent Hertfordshire).
|Net ingredient cost (NIC) of anti-depressant drugs (BNF section 4.3), December 2007-November 2008|
|Net ingredient cost ( £000 )|
This information was obtained from the Prescribing Analysis and CosT tool (PACT) system, which covers prescriptions prescribed by general practitioner, nurses, pharmacists and others in England and dispensed in the community in the United Kingdom. For data at PCT level, prescriptions written by a prescriber located in a particular PCT but dispensed outside that PCT will be included in the PCT in which the prescriber is based. Prescriptions written in England but dispensed outside England are included. Prescriptions written in hospitals /clinics that are dispensed in the community, prescriptions dispensed in hospitals and private prescriptions are not included in PACT data.
Net ingredient cost (NIC)
NIC is the basic cost of a drug. It does not take account of discounts, dispensing costs, fees or prescription charges income.
Figures for the answer were sourced from Prescribing Analysis and CosT Tool (ePACT).
Mr. Lansley: To ask the Secretary of State for Health how many (a) anti-TNF medicines and (b) disease-modifying anti-rheumatic drugs have been (i) prescribed in hospital and (ii) dispensed in the community in each year since 2000-01. 
Disease-modifying anti-rheumatic medicines, including anti-TNF medicines, are listed in the British National Formulary (BNF) chapter 10.1.3Drugs that suppress the rheumatic disease process. The following table shows the total number of prescription items dispensed in the community in England for this category and for anti-TNF medicines.
|Prescription items of disease-modifying anti-rheumatic medicines dispensed in the community in England( 1)|
|BNF chapter 10.1.3 including anti-TNF drugs||Anti-TNF drugs( 2)||BNF chapter 10.1.3 excluding anti-TNF drugs|
|(1) Medicines can be used to treat more than one condition and it is not possible to identify the different conditions that a medicine was prescribed for. Therefore, some of the items included in this table may not have been used to treat rheumatic disease.|
(2) Adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade)
Prescription Cost Analysis system
Phil Hope: Information is not available in the format requested. There are 118 care homes in Hertfordshire that have at least one place registered to provide care for adults with learning disabilities.
There are 1,255 places available in these homes. However, it is should be noted that the homes do not register the actual number of places available for each client group, but indicate which groups they can provide at least one place for.
Norman Lamb: To ask the Secretary of State for Health what funding his Department has provided to external organisations to raise awareness of and provide for patient support for those with brain tumours; and if he will make a statement. 
Ann Keen: The Department provided a total of £34,000 between 2004 and 2007 to Brain Tumour UK, then known as the UK Brain Tumour Society, through section 64 grants (now known as the Third Sector Investment Programme). The grants were provided to enable the charity to raise awareness and provide support for people with brain tumours.
Details of these and other grants to external organisations working to raise awareness and provide support for people with cancer, including brain tumours, is available on the Departments website at:
Sir Robert Smith: To ask the Secretary of State for Health what recent estimate his Department has made of the percentage of newly diagnosed cancer patients who are provided with advice on the financial assistance for which they may be eligible. 
This information is not collected centrally. Advice to patients on sources of financial help is one of the areas to be included in information prescriptions for patients, as proposed in the White Paper Our health, our care, our say: a new direction for community services. A system to enable health care
professionals to generate tailored information prescriptions for cancer patients is expected to be rolled out later this year.
Ann Keen: The Department does not provide training for health care professionals, nor is it responsible for setting curricula for health professional training. However, we do share a commitment with statutory and professional bodies that all health professionals are trained, so that they have the skills and knowledge to deliver a high quality health service to all groups of the population with whom they deal, whatever their condition.
|Implanon Implant 68 mg||Norplant Implant( 1) 38 mg (6 Cap)||Total|
|(1) Norplant Implant is no longer available.|
Prescription information is taken from the PCA system, supplied by NHS Prescription Services, part of the NHS Business Services Authority (BSA), and is based on a full analysis of all prescriptions dispensed in the community in England i.e. by community pharmacists and appliance contractors, dispensing doctors, and prescriptions submitted by prescribing doctors for items personally administered in England. The data do not cover drugs dispensed in hospitals.
|Next Section||Index||Home Page|